This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2016 by University of Chicago
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: April 15, 2011
Last updated: July 20, 2016
Last verified: July 2016
This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.

Condition Intervention Phase
Pancreatic Cancer Radiation: Stereotactic Radiation Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of Stereotactic Body Radiation Therapy in Patients With Unresected Carcinoma of the Pancreas or Ampulla

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Maximum Tolerated Dose [ Time Frame: 28 days ]
    Side effects will be assessed after 28 days of treatment to determine tolerability of the dose of radiation.

Estimated Enrollment: 24
Study Start Date: April 2009
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stereotactic Radiation
Escalating doses of SBRT in three doses over ten days.
Radiation: Stereotactic Radiation
Escalating Doses of SBRT in periods of three doses over 10 days


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed, unresected cancer of the pancreas or ampulla. The cancer may include any invasive histology (e.g. adenocarcinoma, neuroendocrine carcinoma).
  • Patients must have measurable radiographic disease.Patients with previous complete resection are only eligible if there is measurable radiographic disease which is clearly felt to represent locally recurrent disease.
  • Patients may receive any number of cycles of chemotherapy prior to treatment with SBRT, but not within 2 weeks of the first fraction of RT.
  • Age > or = 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 (Karnofsky > or = 60%)
  • Life expectancy of greater than 3 months.
  • Patients must have normal organ and marrow function.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Concurrent investigational therapy delivered over the period of treatment or observation (28 days post-RT) for dose limiting toxicity.
  • Prior radiation therapy to the abdominal area which would overlap with the proposed area of treatment.
  • Pregnancy.
  • Primary disease > 7.5 cm in largest diameter as measured by CT or MRI.
  • Gross extension of tumor into the lumen of the duodenum.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Use of bevacizumab or vascular endothelial growth factor inhibitor chemotherapy within 3 months before RT or 6 months after RT.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01342354

United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Kimberly Janko, RN, BSN    773-702-2856   
Sponsors and Collaborators
University of Chicago
Principal Investigator: Stanley Liauw, MD University of Chicago
  More Information

Responsible Party: University of Chicago Identifier: NCT01342354     History of Changes
Other Study ID Numbers: 16866B
Study First Received: April 15, 2011
Last Updated: July 20, 2016

Keywords provided by University of Chicago:
Pancreatic Cancer
Stereotactic Radiation

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases processed this record on June 23, 2017